Skip to main content
SpringerLink
Log in

Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Olanzapine, a second-generation antipsychotic, is a first-line agent in the treatment of schizophrenia. The objective of this review was to determine whether olanzapine warrants clinical pharmacokinetic monitoring in patients with schizophrenia, using a previously published decision-making algorithm. Although olanzapine is an appropriate therapy for patients with schizophrenia and is readily measurable in biological fluids, significant interindividual variation exists in its pharmacokinetics. While the duration of therapy is expected to be long term, the correlation of olanzapine concentrations with efficacy and toxicity has not been well defined in the literature. There are multiple tools readily available for the assessment of efficacy in schizophrenia, and clinical signs and symptoms can be used to monitor both for efficacy and for adverse effects. Therefore, routine monitoring of olanzapine concentrations does not appear warranted in the general schizophrenic population. However, patients in whom a change in olanzapine pharmacokinetics is expected — such as during addition or removal of an enzyme-inducing or -inhibiting drug, or during initiation or cessation of smoking — may benefit from clinical pharmacokinetic monitoring, as would patients in whom non-compliance is suspected. Patients who fail to respond to maximum recommended doses and those who experience adverse effects from therapeutic doses may also benefit from therapeutic drug monitoring, as they may have inherent variations in hepatic enzyme activity. However, in the population at large who suffer from schizophrenia, monitoring of olanzapine concentrations is not expected to offer additional benefit beyond appropriate clinical monitoring alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Table II

Similar content being viewed by others

Notes

  1. Throughout this review, the terms ‘clinical pharmacokinetic monitoring’ and ‘therapeutic drug monitoring’ (or ‘TDM’) are used interchangeably.

References

  1. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2004; 161: 1–56

    Article  PubMed  Google Scholar 

  2. McGlashan TH. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 1988; 14: 515–42

    Article  PubMed  CAS  Google Scholar 

  3. Dingman CW, McGlashan TH. Discriminating characteristics of suicides: Chestnut Lodge follow-up sample including patients with affective disorder, schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 1986; 74: 91–7

    Article  PubMed  CAS  Google Scholar 

  4. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Arch Gen Psychiatry 1978; 35: 153–5

    Article  PubMed  CAS  Google Scholar 

  5. Hiroeh U, Appleby L, Mortensen PB, et al. Death by homicide, suicide, and other unnatural causes in people with mental illness: a population-based study. Lancet 2001; 358: 2110–2

    Article  PubMed  CAS  Google Scholar 

  6. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45: 21–8

    Article  PubMed  CAS  Google Scholar 

  7. Krausz M, Muller-Thomsen T. Schizophrenia with onset in adolescence: an 11-year followup. Schizophr Bull 1993; 19: 831–41

    Article  PubMed  CAS  Google Scholar 

  8. McGlashan TH, Fenton WS. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull 1993; 19: 71–84

    Article  PubMed  CAS  Google Scholar 

  9. McGlashan TH, Fenton WS. Classical subtypes for schizophrenia: literature review for DSM-IV. Schizophr Bull 1991; 17: 609–32

    Article  PubMed  CAS  Google Scholar 

  10. McGlashan TH. The prediction of outcome in chronic schizophrenia: IV. The Chestnut Lodge follow-up study. Arch Gen Psychiatry 1986; 43: 167–76

    Article  PubMed  CAS  Google Scholar 

  11. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes: II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 1991; 48: 978–86

    Article  PubMed  CAS  Google Scholar 

  12. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes: I. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia. Arch Gen Psychiatry 1991; 48: 969–77

    Article  PubMed  CAS  Google Scholar 

  13. Fenton WS, McGlashan TH. Prognostic scale for chronic schizophrenia. Schizophr Bull 1987; 13: 277–86

    Article  PubMed  CAS  Google Scholar 

  14. Bromet EJ, Fennig S. Epidemiology and natural history of schizophrenia. Biol Psychiatry 1999; 46: 871–81

    Article  PubMed  CAS  Google Scholar 

  15. Bardenstein KK, McGlashan TH. Sex differences in affective, schizoaffective, and schizophrenic disorders: a review. Schizophr Res 1990; 3: 159–72

    Article  PubMed  CAS  Google Scholar 

  16. National Collaborating Centre for Mental Health. Schizophrenia: the NICE guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care [national clinical guideline number 82; online] Available from URL: http://www.nice.org.uk/nicemedia/live/11786/43607/43607.pdf [Accessed 2011 Apr 5]

  17. Baumann P, Hiemke C, Ulrich S, et al.; Arbeitsgemeinschaft für Neuro-psychopharmakologie und Pharmakopsychiatrie. The AGNP-TDM Expert Group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243–65

    Article  PubMed  CAS  Google Scholar 

  18. American Psychiatric Association. Guideline watch (September 2009): practice guideline for the treatment of patients with schizophrenia [online]. Available from URL: http://www.psychiatryonline.com/pracGuide/pracGuideTopic_6.aspx [Accessed 2011 Apr 5]

  19. Ensom MH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes?. Clin Pharma-cokinet 1998; 34: 265–79

    Article  CAS  Google Scholar 

  20. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia [published erratum appears in N Engl J Med 2010; 363: 1092-3]. N Engl J Med 2005; 353: 1209–23

    Article  PubMed  CAS  Google Scholar 

  21. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006; 63: 1079–87

    Article  PubMed  CAS  Google Scholar 

  22. Kahn RS, Fleischhacker WW, Boter H, et al.; EUFEST Study Group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schi-zophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 1085–97

    Article  PubMed  CAS  Google Scholar 

  23. Boter H, Peuskens J, Libiger J, et al.; EUFEST Study Group. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res 2009; 115: 97–103

    Article  PubMed  Google Scholar 

  24. Kasper S, Winkler D. Addressing the limitations of the CATIE study. World J Biol Psychiatry 2006; 7: 126–7

    Article  PubMed  Google Scholar 

  25. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?. Psychol Med 2009; 39: 1591–602

    Article  PubMed  CAS  Google Scholar 

  26. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009; 23: 649–59

    PubMed  Google Scholar 

  27. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31–41

    Article  PubMed  CAS  Google Scholar 

  28. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152–63

    Article  PubMed  Google Scholar 

  29. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6

    Article  PubMed  CAS  Google Scholar 

  30. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553–64

    Article  PubMed  CAS  Google Scholar 

  31. Adams CE, Jayaram M. Do findings from new trials for schizophrenia fit with existing evidence: not duped … just beguiled?. Epidemiol Psychiatr Soc 2007; 16: 199–202

    Google Scholar 

  32. Haro JM, Novick D, Suarez D, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006; 26: 571–8

    Article  PubMed  Google Scholar 

  33. Duggan L, Fenton M, Rathbone J, et al. Olanzapine for schizophrenia. Cochrane Database Syst Rev 2005; (2): CD001359

    PubMed  Google Scholar 

  34. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158: 1149–51

    Article  PubMed  CAS  Google Scholar 

  35. Wright P, Lindborg SR, Birkett M, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry 2003; 48: 716–21

    PubMed  Google Scholar 

  36. Lindborg SR, Beasley CM, Alaka K, et al. Effects of intramuscular olanzapine vs haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res 2003; 119: 113–23

    Article  PubMed  CAS  Google Scholar 

  37. de la Torre SC, Martinez MA, Almarza E. Determination of several psychiatric drugs in whole blood using capillary gas-liquid chromatography with nitrogen phosphorus detection: comparison of two solid phase extraction procedures. Forensic Sci Int 2005; 155: 193–204

    Article  CAS  Google Scholar 

  38. Ulrich S. Assay of olanzapine in human plasma by a rapid and sensitive gas chromatography-nitrogen phosphorus selective detection (GC-NPD) method: validation and comparison with high-performance liquid chroma-tography-coulometric detection. Ther Drug Monit 2005; 27: 463–8

    Article  PubMed  CAS  Google Scholar 

  39. Berna M, Shugert R, Mullen J. Determination of olanzapine in human plasma and serum by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 1998; 33: 1003–8

    Article  PubMed  CAS  Google Scholar 

  40. Berna M, Ackermann B, Ruterbories K, et al. Determination of olanzapine in human blood by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 767: 163–8

    Article  PubMed  CAS  Google Scholar 

  41. Bogusz MJ, Kruger KD, Maier RD, et al. Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 1999; 732: 257–69

    Article  PubMed  CAS  Google Scholar 

  42. Chin C, Zhang ZP, Karnes HT. A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine. J Pharm Biomed Anal 2004; 35: 1149–67

    Article  PubMed  CAS  Google Scholar 

  43. Gervasini G, Vizcaino S, Herraiz AG, et al. Applicability of an assay for routine monitoring of highly variable concentrations of olanzapine based on HPLC with mass spectrometric detection. Clin Chem 2003; 49: 2088–91

    Article  PubMed  CAS  Google Scholar 

  44. Nirogi RV, Kandikere VN, Shukla M, et al. Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma. J Pharm Biomed Anal 2006; 41: 935–42

    Article  PubMed  CAS  Google Scholar 

  45. Josefsson M, Kronstrand R, Andersson J, et al. Evaluation of electrospray ionisation liquid chromatography-tandem mass spectrometry for rational determination of a number of neuroleptics and their major metabolites in human body fluids and tissues. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 789: 151–67

    Article  PubMed  CAS  Google Scholar 

  46. Josefsson M, Roman M, Skogh E, et al. Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethyl-olanzapine in human serum and cerebrospinal fluid. J Pharm Biomed Anal 2010; 53: 576–82

    Article  PubMed  CAS  Google Scholar 

  47. Kirchherr H, Kuhn-Velten WN. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 843: 100–13

    Article  PubMed  CAS  Google Scholar 

  48. Choong E, Rudaz S, Kottelat A, et al. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. J Pharm Biomed Anal 2009; 50: 1000–8

    Article  PubMed  CAS  Google Scholar 

  49. Zhou Z, Li X, Li K, et al. Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 802: 257–62

    Article  PubMed  CAS  Google Scholar 

  50. Nielsen MK, Johansen SS. Determination of olanzapine in whole blood using simple protein precipitation and liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2009; 33: 212–7

    PubMed  CAS  Google Scholar 

  51. Saar E, Gerostamoulos D, Dummer OH, et al. Identification and quantification of 30 antipsychotics in blood using LC-MS/MS. J Mass Spectrom 2010; 45: 915–25

    Article  PubMed  CAS  Google Scholar 

  52. Dusci LJ, Peter Hackett L, Fellows LM, et al. Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet ab-sorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 773: 191–7

    Article  PubMed  CAS  Google Scholar 

  53. D’Arrigo C, Migliardi G, Santoro V, et al. Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 2006; 28: 388–93

    Article  PubMed  CAS  Google Scholar 

  54. Boulton DW, Markowitz JS, De Vane CL. A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. J Chromatogr B Biomed Sci Appl 2001; 759: 319–23

    Article  PubMed  CAS  Google Scholar 

  55. Olesen OV, Poulsen B, Linnet K. Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring. Ther Drug Monit 2001; 23: 51–5

    Article  PubMed  CAS  Google Scholar 

  56. Kollroser M, Schober C. Direct-injection high performance liquid chromatography ion trap mass spectrometry for the quantitative determination of olanzapine, clozapine and N-desmethylclozapine in human plasma. Rapid Commun Mass Spectrom 2002; 16: 1266–72

    Article  PubMed  CAS  Google Scholar 

  57. Sachse J, Koller J, Hartter S, et al. Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 830: 342–8

    Article  PubMed  CAS  Google Scholar 

  58. Sabbioni C, Saracino MA, Mandrioli R, et al. Rapid analysis of olanzapine and desmethylolanzapine in human plasma using high-performance liquid chromatography with coulometric detection. Anal Chim Acta 2004; 516: 111–7

    Article  CAS  Google Scholar 

  59. Aravagiri M, Ames D, Wirshing WC, et al. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Ther Drug Monit 1997; 19: 307–13

    Article  PubMed  CAS  Google Scholar 

  60. Raggi MA, Casamenti G, Mandrioli R, et al. A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure. J Chromatogr B Biomed Sci Appl 2001; 750: 137–46

    Article  PubMed  CAS  Google Scholar 

  61. Catlow JT, Barton RD, Clemens M, et al. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1995; 668: 85–90

    Article  PubMed  CAS  Google Scholar 

  62. Llorca PM, Coudore F, Corpelet C, et al. Integration of olanzapine determinations in a HPLC-diode array detection system for routine psycho-tropic drug monitoring. Clin Chem 2001; 47: 1719–21

    PubMed  CAS  Google Scholar 

  63. Titier K, Bouchet S, Pehourcq F, et al. High-performance liquid chromatographic method with diode array detection to identify and quantify atypical antipsychotics and haloperidol in plasma after overdose. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 788: 179–85

    Article  PubMed  CAS  Google Scholar 

  64. Sturm S, Hammann F, Drewe J, et al. An automated screening method for drugs and toxic compounds in human serum and urine liquid chromato-graphy-tandem mass spectrometry. J Chromatogr B 2010; 878: 2726–32

    Article  CAS  Google Scholar 

  65. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res 1999; 40: 101–4

    Article  PubMed  CAS  Google Scholar 

  66. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, sex, smoking, and comedication. Ther Drug Monit 2003; 25: 46–53

    Article  PubMed  CAS  Google Scholar 

  67. Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 2001; 21: 14–20

    Article  PubMed  CAS  Google Scholar 

  68. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 1999; 21: 87–90

    Article  PubMed  CAS  Google Scholar 

  69. Bergemann N, Frick A, Parzer P, et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 2004; 37: 63–8

    Article  PubMed  CAS  Google Scholar 

  70. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46: 359–88

    Article  PubMed  CAS  Google Scholar 

  71. Mauri MC, Steinhilber CP, Marino R, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 2005; 20: 55–60

    Article  PubMed  CAS  Google Scholar 

  72. Nozawa M, Ohnuma T, Matsubara Y, et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 2008; 30: 35–40

    Article  PubMed  CAS  Google Scholar 

  73. Robertson MD, McMullin MM. Olanzapine concentrations in clinical serum and postmortem blood specimens: when does therapeutic become toxic?. J Forensic Sci 2000; 45: 418–21

    PubMed  CAS  Google Scholar 

  74. Skogh E, Sjodin I, Josefsson M, et al. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol 2011; 31: 4–9

    Article  PubMed  CAS  Google Scholar 

  75. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155: 921–8

    PubMed  CAS  Google Scholar 

  76. Harvey EJ, Taylor DM, Flanagan RJ. D2 receptor occupancy under recommended and high doses of olanzapine. J Psychopharmacol 2001; 15: 213–4

    Article  PubMed  CAS  Google Scholar 

  77. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol 1997; 17: 472–7

    Article  PubMed  CAS  Google Scholar 

  78. Fellows L, Ahmad F, Castle DJ, et al. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. Ther Drug Monit 2003; 25: 682–9

    Article  PubMed  CAS  Google Scholar 

  79. Citrome L, Stauffer VL, Chen L, et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol 2009; 29: 278–83

    Article  PubMed  CAS  Google Scholar 

  80. Kelly DL, Richardson CM, Yu Y, et al. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol 2006; 21: 393–8

    Article  PubMed  CAS  Google Scholar 

  81. Lane HY, Guo SC, Hwang TJ, et al. Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study. J Clin Psychopharmacol 2002; 22: 530–2

    Article  PubMed  Google Scholar 

  82. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76

    Article  PubMed  CAS  Google Scholar 

  83. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766–71

    Article  PubMed  CAS  Google Scholar 

  84. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799–812

    Article  Google Scholar 

  85. Haro J, Kamath S, Ochoa S, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003; 107: 16–23

    Article  Google Scholar 

  86. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21: 911–36

    Article  PubMed  CAS  Google Scholar 

  87. Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006; 88: 63–72

    Article  PubMed  Google Scholar 

  88. Ramaswamy K, Kozma CM, Nasrallah H. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine. Drug Saf 2007; 30: 589–99

    Article  PubMed  CAS  Google Scholar 

  89. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225–35

    Article  PubMed  CAS  Google Scholar 

  90. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004; 64: 701–23

    Article  PubMed  CAS  Google Scholar 

  91. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician 2010; 81: 617–22

    PubMed  Google Scholar 

  92. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68 (Suppl. 1): 20–7

    PubMed  CAS  Google Scholar 

  93. Johnson V, Bruxner G. Neuroleptic malignant syndrome associated with olanzapine. Aust N Z J Psychiatry 1998; 32: 884–6

    Article  PubMed  CAS  Google Scholar 

  94. Bobes J, Garc A Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003; 29: 125–47

    Article  PubMed  CAS  Google Scholar 

  95. Skogh E, Reis M, Dahl ML, et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 2002; 24: 518–26

    Article  PubMed  CAS  Google Scholar 

  96. Perry PJ, Argo TR, Carnahan RM, et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol 2005; 25: 250–4

    Article  PubMed  CAS  Google Scholar 

  97. O’Malley GF, Seifert S, Heard K, et al. Olanzapine overdose mimicking opioid intoxication. Ann Emerg Med 1999; 34: 279–81

    Article  PubMed  Google Scholar 

  98. Capel MM, Colbridge MG, Henry JA. Overdose profiles of new antipsychotic agents. Int J Neuropsychopharmacol 2000; 3: 51–4

    Article  PubMed  CAS  Google Scholar 

  99. Bond GR, Thompson JD. Olanzapine pediatric overdose. Ann Emerg Med 1999; 34: 292–3

    Article  PubMed  CAS  Google Scholar 

  100. Cohen LG, Fatalo A, Thompson BT, et al. Olanzapine overdose with serum concentrations. Ann Emerg Med 1999; 34: 275–8

    Article  PubMed  CAS  Google Scholar 

  101. Stephens BG, Coleman DE, Baselt RC. Olanzapine-related fatality. J Forensic Sci 1998; 43: 1252–3

    PubMed  CAS  Google Scholar 

  102. Trenton A, Currier G, Zwemer F. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 2003; 17: 307–24

    Article  PubMed  CAS  Google Scholar 

  103. Lennestal R, Asplund C, Nilsson M, et al. Serum levels of olanzapine in a non-fatal overdose. J Anal Toxicol 2007; 31: 119–21

    PubMed  CAS  Google Scholar 

  104. Elian AA. Fatal overdose of olanzepine. Forensic Sci Int 1998; 91: 231–5

    Article  PubMed  CAS  Google Scholar 

  105. Gerber JE, Cawthon B. Overdose and death with olanzapine: two case reports. Am J Forensic Med Pathol 2000; 21: 249–51

    Article  PubMed  CAS  Google Scholar 

  106. Chue P, Singer P. A review of olanzapine-associated toxicity and fatality in overdose. J Psychiatry Neurosci 2003; 28: 253–61

    PubMed  Google Scholar 

  107. Bosch RF, Baumbach A, Bitzer M, et al. Intoxication with olanzapine. Am J Psychiatry 2000; 157: 304–5

    Article  PubMed  CAS  Google Scholar 

  108. Attarbaschi T, Sacher J, Geiss-Granadia T, et al. Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine. Eur Neuropsycho-pharmacol 2007; 17: 102–7

    Article  CAS  Google Scholar 

  109. McDonnell D, Detke H, Bergstrom R, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection: II. Investigations of mechanism. BMC Psychiatry 2010; 10: 45

    Article  PubMed  CAS  Google Scholar 

  110. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37: 177–93

    Article  PubMed  CAS  Google Scholar 

  111. Callaghan JT, Cerimele BJ, Kassahun KJ, et al. Olanzapine: interaction study with imipramine. J Clin Pharmacol 1997; 37: 971–8

    PubMed  CAS  Google Scholar 

  112. Shirley KL, Hon YY, Penzak SR, et al. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology 2003; 28: 961–6

    PubMed  CAS  Google Scholar 

  113. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008; 48: 157–65

    Article  PubMed  CAS  Google Scholar 

  114. Bachmann CJ, Haberhausen M, Heinzel-Gutenbrunner M, et al. Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Ther Drug Monit 2008; 30: 108–12

    Article  PubMed  CAS  Google Scholar 

  115. Darby JK, Pasta DJ, Wilson MG, et al. Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study. Clin Drug Investig 2008; 28: 553–64

    Article  PubMed  CAS  Google Scholar 

  116. Carrillo JA, Herraiz AG, Ramos SI, et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23: 119–27

    Article  PubMed  CAS  Google Scholar 

  117. Chiu CC, Lu ML, Huang MC, et al. Heavy smoking, reduced olanzapine levels, and treatment effects: a case report. Ther Drug Monit 2004; 26: 579–81

    Article  PubMed  Google Scholar 

  118. Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006; 62: 1049–53

    Article  PubMed  CAS  Google Scholar 

  119. Wu TH, Chiu CC, Shen WW, et al. Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1889–93

    Article  PubMed  CAS  Google Scholar 

  120. Hagg S, Spigset O, Lakso HA, et al. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol 2001; 57: 493–7

    Article  PubMed  CAS  Google Scholar 

  121. Weiss U, Marksteiner J, Kemmler G, et al. Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol 2005; 25: 570–4

    Article  PubMed  CAS  Google Scholar 

  122. Sathirakul K, Chan C, Teng L, et al. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. Br J Clin Pharmacol 2003; 56: 184–7

    Article  PubMed  CAS  Google Scholar 

  123. Baghdady NT, Banik S, Swartz SA, et al. Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther 2009; 26:404–24

    Article  PubMed  Google Scholar 

  124. Eli Lilly and Company. Zyprexa (olanzapine): US prescribing information [online]. Available from URL: http://pi.lilly.com/us/zyprexa-pi.pdf [Accessed 2011 Apr 5]

  125. Chiu CC, Lane HY, Huang MC, et al. Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol 2004; 44: 1385–90

    Article  PubMed  CAS  Google Scholar 

  126. Hiemke C, Peled A, Jabarin M, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 2002; 22: 502–6

    Article  PubMed  CAS  Google Scholar 

  127. Wang CY, Zhang ZJ, Li WB, et al. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol 2004; 44: 785–92

    Article  PubMed  CAS  Google Scholar 

  128. Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001; 23: 410–3

    Article  PubMed  CAS  Google Scholar 

  129. Markowitz JS, Devane CL, Liston HL, et al. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Clin Pharmacol Ther 2002; 71: 30–8

    Article  PubMed  CAS  Google Scholar 

  130. Penzak SR, Hon YY, Lawhorn WD, et al. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol 2002; 22: 366–70

    Article  PubMed  CAS  Google Scholar 

  131. Gossen D, de Suray JM, Vandenhende F, et al. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002; 4: E11

    Article  PubMed  Google Scholar 

  132. Welden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419–29

    Article  Google Scholar 

Download references

Acknowledgements

No funding was provided to assist in the preparation of the manuscript. The authors have no potential conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada

    Erin Schwenger, Jane Dumontet &  Mary H. H. Ensom

  2. Cottonwood, Connolly and Cypress Lodges, Fraser Health, Coquitlam, BC, Canada

    Jane Dumontet

  3. Pharmacy Department (0B7), Children’s and Women’s Health Centre of British Columbia, 4500 Oak Street, Vancouver, BC, V6H 3N1, Canada

    Mary H. H. Ensom

Authors
  1. Erin Schwenger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jane Dumontet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mary H. H. Ensom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary H. H. Ensom.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwenger, E., Dumontet, J. & Ensom, M.H.H. Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?. Clin Pharmacokinet 50, 415–428 (2011). https://doi.org/10.2165/11587240-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11587240-000000000-00000

Keywords

Search

Navigation